Würth Roberto, Pattarozzi Alessandra, Barbieri Federica, Florio Tullio
Sezione di Farmacologia, Dipartimento di Medicina Interna (DiMI) & Centro di Eccellenza per la Ricerca Biomedica (CEBR), Università di Genova, Genova, Italy.
Bio Protoc. 2018 Apr 5;8(7):e2790. doi: 10.21769/BioProtoc.2790.
Pituitary adenomas are among the more frequent intracranial tumors usually treated with both surgical and pharmacological-based on somatostatin and dopamine agonists-approaches. Although mostly benign tumors, the occurrence of invasive behaviors is often detected resulting in poorer prognosis. The use of primary cultures from human pituitary adenomas represented a significant advancement in the knowledge of the mechanisms of their development and in the definition of the determinants of their pharmacological sensitivity. Moreover, recent studies identified also in pituitary adenomas putative tumor stem cells representing, according to the current hypothesis, the real cellular targets to eradicate most malignancies. In this protocol, we describe the procedure to establish primary cultures from human pituitary adenomas, and how to select, expand, and phenotypically characterize putative pituitary adenoma stem cells.
垂体腺瘤是较为常见的颅内肿瘤,通常采用手术和基于生长抑素及多巴胺激动剂的药物治疗方法。尽管大多为良性肿瘤,但常检测到侵袭性行为的发生,导致预后较差。使用人垂体腺瘤的原代培养物,在了解其发生机制以及确定其药理敏感性的决定因素方面取得了重大进展。此外,最近的研究还在垂体腺瘤中发现了假定的肿瘤干细胞,根据目前的假说,这些干细胞是根除大多数恶性肿瘤的真正细胞靶点。在本方案中,我们描述了从人垂体腺瘤建立原代培养物的程序,以及如何选择、扩增和对假定的垂体腺瘤干细胞进行表型特征分析。